Aerie Pharmaceuticals: Dedicated to Meeting Your Therapeutic Needs
We are an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma, retinal diseases and other diseases of the eye.
OUR VISIONaerie® LEGACY
Our VISIONaerie® co-founder, David L. Epstein, M.D. (1943-2014), established Aerie to discover a drug that targets the main cause of elevated IOP in glaucoma – the diseased trabecular meshwork (TM).MORE
THE TRABECULAR MESHWORK
The TM is a natural therapeutic target in open-angle glaucoma. Degenerative changes in the TM may cause a decrease in outflow of aqueous humor, depriving the tissue of nutrients and leading to elevated IOP.MORE
ROCK inhibitors, representing the first new class of drugs to treat elevated IOP introduced in the United States in more than 20 years, target the TM at the cellular level.MORE